All lobbying filings

DESIMONE CONSULTING, LLC

DESIMONE CONSULTING, LLC filed a Q4 report for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) on January 17, 2026, reporting $40,000 in lobbying income.

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) · trade group representing U.S. pharmaceutical research and biotechnology companies

All filings by DESIMONE CONSULTING, LLC · Everything PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 17, 2026

Income

$40,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Pharmacy

Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to 340B reform. Issues related to the EPIC (Ensuring Pathways to Innovative Cures) Act, H.R.1492/S.832. Issues related to Most Favored Nation (MFN) policy. Issues related to PBM reform; H.R.4317, PBM Reform Act of 2025 and S.3345, PBM Price Transparency and Accountability Act.

Bills named in this filing 4

H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S. 832
EPIC Act of 2025
H.R. 4317
PBM Reform Act of 2025
S. 3345
PBM Price Transparency and Accountability Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.